Gilberto de Lima Lopes Junior, Chief of the Division of Medical Oncology at the Sylvester Comprehensive Cancer Center, shared on LinkedIn:
“Curious about GLP-1 agonists and cancer? Here is a structured summary and critical appraisal of ASCO26 presentations.
In summary, 28 observational studies across ≥12 cancers overwhelmingly linked GLP-1 therapies with better cancer outcomes in prevention, downstaging, and survival in advanced disease. But shared biases may explain much of the benefit. The signal warrants prospective randomized trials – not prescribing GLP-1 drugs to prevent or treat cancer. But these agents are shaping up to become longevity drugs if we can prove these benefits.”
Title: GLP-1 Receptor Agonists and Cancer: Interpreting a Wave of Real-World Signals From the 2026 ASCO Annual Meeting
Authors: Natallia Starasvetskaya, Fernando Gerchman, Gilberto de Lima Lopes Junior
Other articles featuring Gilberto de Lima Lopes.